DIAGNOSTIC TEST 130
Golimumab
Diagnostic test for monitoring of the Golimumab level and control of Anti-Drug Antibodies (ADA) against the drug.
Indication
Monitoring of Golimumab level and control of Anti-Drug Antibodies (ADA)
Sample material
Serum
- Minim. volume: 0,7 mL
Transport
- Within Sweden: room temperature
- International: room temperature
Method
- Drug concentration: ELISA
- Anti-Drug Antibodies (ADA): RIA
Result
Drug concentration is reported as µg/mL. At drug concentrations <1 µg/mL it is recommended to further test for ADA. ADA is reported as a concentration (AU/mL).
Interpretation
Golimumab acts as a TNF-alpha inhibitor. The sample should be drawn at trough value. Low or unmeasurable concentration of the biologic pharmaceutical is associated with poor clinical effect. One explanation can be that antibodies against the drug (anti-drug antibodies, ADA) block the drug and enhance the clearance of the drug.
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.7 mL serum (plain serum tubes without additives).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
